SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE COMBINATION OF SORAFENIB AND TANESPIMYCIN

PURPOSE: Heat shock protein 90 inhibition affects the Raf-kinase signaling pathway and could enhance anti-tumor effects of sorafenib, a Raf-kinase inhibitor. The combination of sorafenib and tanespimycin (17-AAG/17-allyl-amino-geldanamycin; NSC # 330507/KOS-953) was evaluated in a phase I trial with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vaishampayan, Ulka N., Burger, Angelika M., Sausville, Edward A., Heilbrun, Lance K., Li, Jing, Horiba, Naomi, Egorin, Merrill J., Ivy, Percy, Pacey, Simon, Lorusso, Patricia M.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2909581/
https://ncbi.nlm.nih.gov/pubmed/20525756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0503
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars